Drilldown: Medicines

Asenapine (1) · Chlorpromazine (1) · Droperidol (1) · Etodolac (1) · Fluphenazine (1) · Iloperidone (1) · Loxapine (1) · Lurasidone (1) · Molindone (1) · Nabumetone (1) · Paliperidone (1) · Perphenazine (1) · Pimozide (1) · Prochlorperazine (1) · Thioridazine (1) · Thiothixene (1) · Trifluoperazine (1) · Ziprasidone (1)

Compazine (1) · Fanapt (1) · Geodon (1) · Inapsine (1) · Invega (1) · Latuda (1) · Lodine (US brand discontinued); generic (1) · Loxitane (1) · Mellaril (1) · Moban (1) · Navane (1) · Orap (1) · Prolixin (1) · Relafen (1) · Saphris (1) · Stelazine (1) · Thorazine (1) · Trilafon (1)

Research material · Classic Psychedelic · Stimulant · Opioid · Sedative-hypnotic · Phenethylamine · Tryptamine · Benzodiazepine · Botanical · [[:Category:Antihypertensives|Antihypertensive]] · Dissociative · Anticonvulsant · Antidepressant · Plant Medicine · Analgesic · Antiparkinsonian · Antipsychotic · Empathogen · Neuroleptic · Cathinone

Other values:

Search

Butyrophenone D2 antagonist (1) · D2 receptor antagonist; also H1, alpha-1, muscarinic antagonist (1) · D2/5-HT2A antagonist (1) · D2/5-HT2A antagonist; 5-HT7 antagonist (1) · D2/5-HT2A antagonist; active metabolite of risperidone (1) · D2/5-HT2A antagonist; SRI and NRI (1) · Dibenzoxazepine D2/5-HT2 antagonist (1) · Dihydroindolone D2 antagonist (1) · Diphenylbutylpiperidine D2 antagonist (1) · Multi-receptor antagonist (D2, 5-HT2A, H1, alpha) (1) · Phenothiazine D2 antagonist (5) · Thioxanthene D2 antagonist (1) · '"`UNIQ--vote-000011F4-QINU`"' Like all NSAIDs, raises CV thrombotic risk modestly (FDA 2014/2015 advisory) and produces GI, renal, hypertensive, and platelet-inhibitory effects characteristic of the class'"`UNIQ--ref-000011F5-QINU`"'. (1) · '"`UNIQ--vote-00001269-QINU`"' Renal, GI, hypertensive, and CV effects parallel the class profile; modest COX-2 preference may underlie some literature suggesting slightly better GI tolerability than non-selective NSAIDs, though clinically the difference is small'"`UNIQ--ref-0000126A-QINU`"'. (1)

None (16) · '"`UNIQ--vote-000011F6-QINU`"', '"`UNIQ--vote-000011F7-QINU`"', '"`UNIQ--vote-000011F8-QINU`"' (1) · '"`UNIQ--vote-0000126B-QINU`"', '"`UNIQ--vote-0000126C-QINU`"', '"`UNIQ--vote-0000126D-QINU`"' (1)

None (16) · 1000 mg PO once daily; 500-2000 mg/d in single or divided doses (1) · IR 200-400 mg PO every 6-8 hours; ER 400-1000 mg PO once daily (1)

None (16) · 200, 300, 400, 500 mg IR tablets/capsules; 400, 500, 600 mg ER tablets (1) · 500, 750 mg tablets (1)

None (16) · 1000 mg/d (osteoarthritis); 1200 mg/d (rheumatoid arthritis) (1) · 2000 mg/d (1)

None (16) · Oral (2)

None (16) · Analgesia within 30 minutes; full anti-inflammatory effect over days (1) · Analgesia within hours; anti-inflammatory effect over days (1)

None (16) · 24 hours (1) · 6-8 hours (IR); 24 hours (ER) (1)

None (16) · ~24 hours (6-methoxy-2-naphthylacetic acid, the active metabolite)'"`UNIQ--ref-000011F9-QINU`"' (1) · ~7 hours'"`UNIQ--ref-0000126E-QINU`"' (1)

None (16) · ~100% (oral; absorption complete)'"`UNIQ--ref-0000126F-QINU`"' (1) · ~38% (oral; non-acidic prodrug improves GI tolerability over many other NSAIDs)'"`UNIQ--ref-000011FA-QINU`"' (1)

None (16) · Avoid after 20 weeks (NSAID-class FDA 2020 advisory on fetal renal injury and oligohydramnios with second/third-trimester use).<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1) · Avoid after 20 weeks (NSAID-class FDA 2020 advisory).<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1)

None (16) · [[USLegal:Prescription only|Rx-only]] in US. Carries the NSAID-class '''Boxed Warning''' for cardiovascular thrombotic events and serious GI bleeding'"`UNIQ--ref-000011FB-QINU`"' (1) · [[USLegal:Prescription only|Rx-only]] in US. NSAID-class '''Boxed Warning''' for CV thrombotic events and GI bleeding'"`UNIQ--ref-00001270-QINU`"' (1)